Results 221 to 230 of about 251,708 (339)

Availability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Introduction Bevacizumab, a vascular endothelial growth factor inhibitor, is used off‐label for treatment of severe anaemia related to epistaxis, gastrointestinal bleeding and/or severe hepatic arteriovenous malformations (HAVM) and right‐sided cardiac failure in patients with hereditary haemorrhagic telangiectasia (HHT).
Pernille D. Haahr   +18 more
wiley   +1 more source

Assessing changes on large cerebral arteries in CADASIL: Preliminary insights from a case-control analysis. [PDF]

open access: yesJ Stroke Cerebrovasc Dis
Lopez-Navarro ER   +11 more
europepmc   +1 more source

Pentoxifylline dose finding trial in preterm neonates with suspected late onset sepsis (PTX‐trial)

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim The aim of this study (PTX‐trial) is to determine the optimal dose of pentoxifylline (PTX) in preterm neonates (gestational age < 30 weeks) with (suspected) late onset sepsis (LONS). Methods The PTX‐trial is a prospective multicentre open‐label sequential dose‐optimization study with an adapted continual reassessment method.
Serife Kurul   +7 more
wiley   +1 more source

Gene expression changes in human cerebral arteries following hemoglobin exposure: implications for vascular responses in SAH. [PDF]

open access: yesFront Physiol
Shafeeque CM   +6 more
europepmc   +1 more source

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence for regulatory science and innovation in pharmacogenomics (CERSI‐PGx)

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Clopidogrel, an antiplatelet agent, is currently licensed in the United Kingdom for the prevention and treatment of atherothrombotic events in cerebrovascular disease, coronary artery disease and peripheral arterial disease. Clopidogrel requires metabolic activation by the cytochrome P450 enzyme CYP2C19 to be effective.
Cinzia Dello Russo   +22 more
wiley   +1 more source

Cerebrovascular longitudinal atlas: Changes in cerebral arteries in unruptured intracranial aneurysm patients followed with MRA. [PDF]

open access: yesNeuroimage Clin
Chien A   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy